Baseline demographic and clinical characteristics of treated patients
| Characteristic | N + S (N = 33) | N + P (N = 20) |
|---|---|---|
| Age, years | ||
| Median (range) | 57.0 (38–75) | 56.0 (40–72) |
| Age <65 years, n (%) | 24 (72.7) | 17 (85.0) |
| Sex, n (%) | ||
| Male | 26 (78.8) | 18 (90.0) |
| Female | 7 (21.2) | 2 (10.0) |
| Race, n (%) | ||
| Caucasian | 28 (84.8) | 18 (90.0) |
| Asian | 1 (3.0) | 0 |
| Black/African American | 2 (6.1) | 1 (5.0) |
| Other | 2 (6.1) | 1 (5.0) |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 2 (6.1) | 0 |
| Not Hispanic/Latino | 29 (87.9) | 18 (90.0) |
| Not reported | 2 (6.1) | 2 (10.0) |
| MSKCC risk category, n (%) | ||
| Favorable | 16 (48.5) | 4 (20.0) |
| Intermediate | 16 (48.5) | 14 (70.0) |
| Poor | 1 (3.0) | 2 (10.0) |
| Prior surgery, n (%) | 33 (100.0) | 20 (100.0) |
| Prior radiotherapy, n (%) | 5 (15.2) | 10 (50.0) |
| Prior systemic therapy, n (%) | 14 (42.4) | 20 (100.0) |
| VEGFR inhibitor | 5 (15.2) | 17 (85.0) |
| Other antiangiogenic | 7 (21.2) | 17 (85.0) |
| Cytokine | 9 (27.3) | 10 (50.0) |
| mTOR inhibitor | 0 | 3 (15.0) |
| Other | 3 (9.1) | 4 (20.0) |
| No. of prior therapies, n (%) | ||
| 0 | 19 (57.6) | 0 |
| 1 | 14 (42.4) | 14 (70.0) |
| 2 | 0 | 4 (20.0) |
| 3 | 0 | 1 (5.0) |
| ≥4 | 0 | 1 (5.0) |
| Treatment setting, an (%) | ||
| Adjuvant | 3 (9.1) | 4 (20.0) |
| Metastatic | 0 | 2 (10.0) |
| Neoadjuvant | 11 (33.3) | 16 (80.0) |
aMore than one setting per patient may be reflected in the frequency